Carolina BioOncology Institute

Summary

Carolina BioOncology Institute is a medical facility located in Huntersville, North Carolina. This center is recognized for care of Solid Tumors, Lung Cancer, Cancer, Breast Cancer, Pancreatic Cancer and other specialties. Carolina BioOncology Institute is involved with conducting 94 clinical trials across 87 conditions. There are 2 research doctors associated with this hospital, such as John Powderly, M.D. and John D. Powderly II, MD.

Top PIs

Clinical Trials running at Carolina BioOncology Institute

Cancer

Solid Tumors

Pancreatic Cancer

Lung Cancer

Breast Cancer

Colorectal Cancer

Ovarian Cancer

Squamous Cell Carcinoma

Bladder Cancer

Cervical Cancer

ABBV-514 + Budigalimab

for Lung & Head and Neck Cancers

This trial is testing two experimental drugs, ABBV-514 and Budigalimab, on adults with specific types of cancer. The goal is to find out if these drugs can help treat lung and head/neck cancers by monitoring their effects and side effects.

Recruiting

1 award

Phase 1

RBS2418

for Cancer

This trial is testing a new drug called RBS2418, alone or with pembrolizumab, for patients with advanced tumors who haven't responded to other treatments. The drug works by boosting the body's natural defenses to better recognize and destroy cancer cells.

Recruiting

1 award

Phase 1

ABBV-CLS-484 + PD-1/VEGFR Inhibitors

for Cancer

The study will assess the safety, PK, PD, and preliminary efficacy of ABBVCLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The trial aims to establish a safe, tolerable, and efficacious dose of ABBVCLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation and Part 3 Dose Expansion (Monotherapy and Combination therapy). Part 1, ABBV-CLS-484 will be administered alone in escalating dose levels to eligible subjects who have advanced solid tumors. Part 2, ABBV-CLS-484 will be administered at escalating dose levels in combination with a PD-1 targeting agent or with a VEGFR TKI to eligible subjects who have advanced solid tumors. Part 3, ABBV-CLS-484 will be administered alone as a monotherapy at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1 targeting or with a VEGFR TKI agent in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1/PD-L1, and advanced ccRCC.

Recruiting

1 award

Phase 1

10 criteria